Dingyao Hu

机构：Peking University, Peking University Cancer Hospital, Beijing Hospital

发表论文 23 篇 · 总被引 98 次 · h-index 5

代表论文

Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy (2022 · BMC Medicine · 被引 32)
Anti‐CD47 immunotherapy in combination with BCL‐2 inhibitor to enhance anti‐tumor activity in B‐cell lymphoma (2022 · Hematological Oncology · 被引 25)
The effectiveness and safety of beta antagonist in burned patients: A systematic review and meta‐analysis (2020 · International Wound Journal · 被引 11)
PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4/6 inhibitor palbociclib via PLK1 in B-cell lymphoma (2024 · Cancer Letters · 被引 9)
EZH2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor Chidamide through STAT1 in T-cell lymphoma (2025 · Cell Death and Disease · 被引 5)
Ibrutinib combined with low‐dose histone deacetylases inhibitor chidamide synergistically enhances the anti‐tumor effect in B‐cell lymphoma (2022 · Hematological Oncology · 被引 4)